688217.SHG Shanghai Rightongene Biotechnology Co. Ltd. A
- Market cap
- CNY 1.15B
- P/E
- -
- P/B
- 1.36x
- ROE
- -3.0%
- Dividend yield
- 0.83%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688217.SHG undervalued?
Graham numberThe Graham number of Shanghai Rightongene Biotechnology Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Rightongene Biotechnology Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai Rightongene Biotechnology Co. Ltd. A yet.
Shanghai Rightongene Biotechnology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Rightongene Biotechnology Co. Ltd. A
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to…
Full company profileShanghai Rightongene Biotechnology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Rightongene Biotechnology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 255M | 285M | 291M | 424M | 258M | 242M | 177M | 160M |
| Gross Profit | 206M | 205M | 213M | 258M | 189M | 181M | 134M | 124M |
| Operating Income | 40.0M | 45.0M | 34.2M | 86.3M | 352K | -9.26M | -11.0M | -3.68M |
| EBITDA | 57.1M | 68.5M | 80.5M | 108M | 35.8M | 18.1M | -10.6M | -20.6M |
| Net Income | 35.9M | 38.7M | 47.3M | 40.5M | 7.93M | -15.8M | -50.4M | -24.7M |
| EPS | 0.86 | 0.93 | 0.85 | 0.73 | 0.14 | -0.28 | -0.90 | -0.44 |
| Balance Sheet | ||||||||
| Total Assets | 656M | 723M | 948M | 1.08B | 1.04B | 986M | 885M | 862M |
| Total Liabilities | 47.8M | 61.1M | 50.9M | 112M | 76.5M | 65.1M | 39.2M | 33.4M |
| Shareholders' Equity | 608M | 647M | 889M | 937M | 946M | 909M | 845M | 833M |
| Cash & Short-term Investments | 128M | 142M | 123M | 204M | 162M | 139M | 105M | 138M |
| Cash Flow | ||||||||
| Operating Cash Flow | 11.7M | 70.1M | 78.0M | 73.1M | 45.1M | 60.0M | 45.5M | - |
| Capital Expenditure | 53.8M | 52.1M | 95.6M | 107M | 109M | 39.4M | 26.8M | 1.63M |
| Free Cash Flow | -42.1M | 18.0M | -17.6M | -33.5M | -64.0M | 20.6M | 18.8M | 23.8M |
| Ratios | ||||||||
| ROE | 5.9% | 6.0% | 5.3% | 4.3% | 0.8% | -1.7% | -6.0% | -3.0% |
| ROA | 5.5% | 5.4% | 5.0% | 3.7% | 0.8% | -1.6% | -5.7% | -2.9% |
| Net Profit Margin | 14.1% | 13.6% | 16.3% | 9.5% | 3.1% | -6.5% | -28.4% | -15.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Rightongene Biotechnology Co. Ltd. A dividends
- Dividend yield
- 0.83%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Oct 24, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 9.50M | 0.17 | - |
| 2024 | CNY 620K | 0.01 | - |
| 2023 | CNY 10.4M | 0.19 | 131.1% |
| 2022 | CNY 11.0K | 0.00 | 0.0% |
| 2021 | CNY 19.5K | 0.00 | 0.0% |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shanghai Rightongene Biotechnology Co. Ltd. A
- Insiders 37.09%
- Institutions 13.78%
- Public & others 49.13%
- Shares outstanding 55.9M
- Free float 32.5M
Shanghai Rightongene Biotechnology Co. Ltd. A company profile
- Company name
- Shanghai Rightongene Biotechnology Co. Ltd. A
- Ticker
- 688217.SHG
- ISIN
- CNE100005212
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 336
- Fiscal year end
- December
- Address
- No. 147, Lane 1817, Shanghai, China, 201403
- Phone
- 86 21 3328 2601
- Website
- rightongene.com
About Shanghai Rightongene Biotechnology Co. Ltd. A
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to leukemia, lymphoma, solid tumors, and infectious diseases. In addition, it provides third-party medical testing services to various medical institutions, pharmaceutical companies, and individual patients, as well as gene testing research services to research hospitals, pharmaceutical companies, research institutions, and other third-party testing organizations. Shanghai Rightongene Biotechnology Co., Ltd. was founded in 2012 and is based in Shanghai, China.
Shanghai Rightongene Biotechnology Co. Ltd. A management
4- Mr. Shangxian GaoChairman & GM · born 1957
- Mr. Zhong He KeR&D Director and Director · born 1986
- Ms. Chengli ZhangDeputy General Manager · born 1958
- Ms. Liqun XieDeputy General Manager · born 1964